ImmBio is a venture-capital based biotechnology company. It issued capital through a “Series C” funding round in November 2005, raising €10 million, with follow-on provisions. This funding complements the collaborative agreement with Aeras Global TB Foundation and a number of grants.

Current funds enable ImmBio to progress a selection of its portfolio through pre-clinical into early clinical.

Our investors are:

• Avlar BioVentures
• Chord Capital (formerly Generics Asset Management)
• Hygea  VCT (formerly Biosciences VCT, Octopus Investments)
• Inventages Venture Capital
• Oxford Technology VCT
• Yorkshire Fund Managers

At each funding round, the prior investors have subscribed to new equity, based on continuing good progress of ImmBio.